The international, non-interventional, Coptimze trial of glatiramer acetate injection in relapsing-remitting multiple sclerosis.

Trial Profile

The international, non-interventional, Coptimze trial of glatiramer acetate injection in relapsing-remitting multiple sclerosis.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2014

At a glance

  • Drugs Glatiramer acetate (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms Coptimize
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 15 Apr 2011 Preliminary results have been presented at AAN-2011 according to a Teva Pharmaceutical Industries media release; results were also reported in the media release.
    • 15 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top